ClinicalTrials.gg
Drug

Gonadotropin-Releasing Hormone clinical trials

Also written GnRH.

studies test it
33
open now
3
in phase 3
7
first study started
1994

How each study uses Gonadotropin-Releasing Hormone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Gonadotropin-Releasing Hormone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
10 Oct 1989 · LUTREPULSE KIT · NDA 019687 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

gonadotropin-releasing hormone
4
gonadotropin releasing hormone (GnRH)
3
LutrePulse
2
Gonadotropin-releasing hormone (GnRH)
2
Gonadotropin Releasing Hormone Agonists (GNRH)
2

Other names

GnRH
7
Gonadorelin
3
luteinizing hormone-releasing factor
1

In one entry with another drug

Given together, or one or the other

Lutrepulse
2

Studies by the year they started

30 studies that test it; most in 2011 (3)

Studies that test Gonadotropin-Releasing Hormone, by start year
YearStudies
19941
19981
19991
20001
20012
20021
20041
20051
20092
20101
20113
20142
20152
20161
20192
20201
20211
20222
20232
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
9
Phase 3
7
Phase 4
5
No phase
11

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 5 · Other 28

Massachusetts General Hospital (4) · Ferring Pharmaceuticals (4) · University of Colorado, Denver (4) · Radiation Therapy Oncology Group (2) · Stephanie B. Seminara, MD (2) · University Reproductive Associates (1) · Hoffmann-La Roche (1) · University of British Columbia (1)

Often tested with

Tested in the same studies.

Paclitaxel (2) · KISS1 protein, human (2) · Gonadorelin diacetate tetrahydrate (2) · Estrogens (2) · Progesterone (2) · Chorionic Gonadotropin (2) · Androgen Receptor Antagonists (2) · Ipatasertib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test Gonadotropin-Releasing Hormone.

Studies

Open first, then newest update. How each study uses Gonadotropin-Releasing Hormone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 33

See all 33 studies that test Gonadotropin-Releasing Hormone →

Given beside what is tested · 29 — Gonadotropin-Releasing Hormone is usual care or a partner of the new treatment

Showing 20 of 29.

Codes

What other systems call Gonadotropin-Releasing Hormone · ClinicalTrials.gg INT007734

Also registered as gonadorelin (UNII 9O7312W37G · RxNorm 6384) and gonadorelin acetate (UNII 2RG1XQ1NYJ · RxNorm 204193).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.